1-6 of 6
Damian L. Szatkowski
Close
Sort by
Journal Articles

A Prospective Phase 2 Study to Assess Minimal Residual Disease after Ixazomib, Lenalidomide and Dexamethasone Treatment for Newly Diagnosed Transplant Eligible Multiple Myeloma Patients

Raija Helena Silvennoinen, MDPhD, Anders Waage, MD PhD, Valdas Peceliunas, MD, Fredrik Schjesvold, MDPhD, Pekka Anttila, MD, Marjaana Säily, MD PhD, Mervi Putkonen, MD PhD, Kristina Carlson, MD, Einar Haukaas, MD, Marja Sankelo, MDPhD, Anu Partanen, MD PhD, Damian L. Szatkowski, MDPhDMSc, Markus Hansson, MD PhD, Anu Marttila, MD, Lucia Ahlberg, MD, Per Axelsson, MD, Birgitta Lauri, MD, Maija Helena Mikkola, MD, Conny Karlsson, MD, Johanna Abelsson, MD, Erik Ahlstrand, MD PhD, Anu Sikiö, MD, Monika Klimkowska, MD PhD, Reda Matuzeviciene, MD PhD, Mona Hoysaeter Fenstad, MD PhD, Sorella Ilveskero, MD PhD, Hareth Nahi, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 40–41.
https://doi.org/10.1182/blood-2020-138643
Published: 2020
Journal Articles

Ixazomib-Thalidomide-Low Dose Dexamethasone (ITd) Induction Followed By Maintenance Therapy with Ixazomib or Placebo in Newly Diagnosed Multiple Myeloma Patients Not Eligible for Autologous Stem Cell Transplantation; Results from the Randomized Phase II HOVON-126/Nmsg 21#13 Trial

Sonja Zweegman, MDPhD, Fredrik H. Schjesvold, MDPhD, Bronno van der Holt, PhD, Mark-David Levin, MDPhD, Claudia A.M. Stege, MD, Anders Waage, MD PhD, Maria B.L. Leijs, MD, Saskia K. Klein, MDPhD, Damian L. Szatkowski, MDPhDMSc, Per Axelsson, MD, Trung Hieu Do, MD, Dorota Knut-Bojanovska, Ellen van der Spek, MDPhD, Asta Svirskaite, Pino Poddighe, MDPhD, Marian Stevens-Kroef, MD, Markus Hansson, MD PhD, Niels WCJ van de Donk, MD PhD, Einar Haukas, MD, Pieter Sonneveld, MDPhD, Niels Abildgaard, MDPhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 800.
https://doi.org/10.1182/blood-2018-99-111650
Published: 2018
Journal Articles

Ixazomib-Thalidomide-Low Dose Dexamethasone (ITd) Induction Followed By Maintenance Therapy with Ixazomib or Placebo in Newly Diagnosed Multiple Myeloma Patients Not Eligible for Autologous Stem Cell Transplantation; Initial Results from the Randomized Phase II HOVON-126/Nmsg 21.13 Trial

Sonja Zweegman, MD PhD, Bronno van der Holt, Fredrik H. Schjesvold, MDPhD, Mark-David Levin, PhD, Claudia A.M. Stege, MD, Anders Waage, MD PhD, Maria Berhardina Leijs, MD, Saskia Klein, MD, Damian L. Szatkowski, MDPhDMSc, A Broyl, MDPhD, Per Axelsson, MD, Trung Hieu Do, MD, Dorota Knut-Bojanovska, Ellen van der Spek, MD, Asta Svirskaite, Sonia Cunha, Markus Hansson, MD PhD, Pieter Sonneveld, MDPhD, Einar Haukaas, Niels Abildgaard, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 433.
https://doi.org/10.1182/blood.V130.Suppl_1.433.433
Published: 2017
Journal Articles

Frailty Predicts Survival and Toxicity in Newly Diagnosed Multiple Myeloma Patients Ineligible for Autologous Stem Cell Transplantation; Report of the HOVON-87/Nmsg-18 Study Group

Claudia A.M. Stege, MD, Bronno van der Holt, Ulf-Henrik Mellqvist, MD, Mark-David Levin, PhD, Morten Salomo, Niels Abildgaard, MD, Gerard Bos, MDPhD, Heleen Visser-Wisselaar, Markus Hansson, MD PhD, Annette van der Velden, MD, Wendy Deenik, MD, Astrid Gruber, MD PhD, Jules L.L.M. Coenen, MD, Torben Plesner, MD, Saskia Klein, MD, Bea Tanis, MD PhD, Damian L. Szatkowski, MDPhDMSc, Rolf Brouwer, MD PhD, Matthijs Westerman, MD, Maria Berhardina Leijs, MD, Harm Sinnige, Einar Haukaas, Klaas van der Hem, MD PhD, Marc Durian, MD, Vera Mattijssen, MD PhD, Peter Gimsing, DO, PhD, Niels WCJ Van De Donk, Marian Stevens-Kroef, PhD, Pieter Sonneveld, MDPhD, Anders Waage, MD PhD, Sonja Zweegman, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3146.
https://doi.org/10.1182/blood.V130.Suppl_1.3146.3146
Published: 2017
Journal Articles

Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma

Clinical Trials & Observations
Sonja Zweegman, Bronno van der Holt, Ulf-Henrik Mellqvist, Morten Salomo, Gerard M. J. Bos, Mark-David Levin, Heleen Visser-Wisselaar, Markus Hansson, Annette W. G. van der Velden, Wendy Deenik, Astrid Gruber, Juleon L. L. M. Coenen, Torben Plesner, Saskia K. Klein, Bea C. Tanis, Damian L. Szatkowski, Rolf E. Brouwer, Matthijs Westerman, M. (Rineke) B. L. Leys, Harm A. M. Sinnige, Einar Haukås, Klaas G. van der Hem, Marc F. Durian, E. (Vera) J. M. Mattijssen, Niels W. C. J. van de Donk, Marian J. P. L. Stevens-Kroef, Pieter Sonneveld, Anders Waage
Journal: Blood
Blood (2016) 127 (9): 1109–1116.
https://doi.org/10.1182/blood-2015-11-679415
Published: 2016
Includes: Supplemental data
Journal Articles

Randomized Phase III Trial in Non-Transplant Eligible Patients with Newly Diagnosed Symptomatic Multiple Myeloma Comparing Melphalan-Prednisone-Thalidomide Followed By Thalidomide Maintenance (MPT-T) Versus Melphalan-Prednisone-Lenalidomide Followed By Maintenance with Lenalidomide (MPR-R); A Joint Study of the Dutch-Belgian Cooperative Trial Group for Hematology Oncology (HOVON) and the Nordic Myeloma Study Group (NMSG)

Sonja Zweegman, MDPhD, Bronno van der Holt, PhD, Ulf-Henrik Mellqvist, MDPhD, Morten Salomo, MD, Gerard M.J. Bos, MDPhD, Mark-David Levin, MDPhD, Heleen A Visser-Wisselaar, PhD, Markus Hansson, MD PhD, Annette WG van der Velden, MD, Wendy Deenik, MDPhD, Astrid Gruber, MDPhD, Juleon LLM Coenen, MD, Torben Plesner, MD, Saskia K Klein, MDPhD, Bea Tanis, MDPhD, Damian L Szatkowski, MDPhDMSc, Rolf Brouwer, MDPhD, Matthijs Westerman, MD, M (Rineke) BL Leys, MDPhD, Niels W.C.J. van de Donk, MDPhD, Einar Haukås, MD, Klaas van der Hem, MD PhD, MF Durian, MD, E (Vera) JM Mattijssen, MDPhD, Harm AM Sinnige, MDPhD, Marian JPL Stevens-Kroef, PhD, Pieter Sonneveld, MDPhD, Anders Waage, MD PhD
Journal: Blood
Blood (2014) 124 (21): 179.
https://doi.org/10.1182/blood.V124.21.179.179
Published: 2014